AI lesion analysis
Original image, lesion heatmap, and boundary controls are reviewed side by side.
Dermatology AI SaaS
AI-assisted skin lesion review, built for clinical teams that need evidence.
Dermascribe helps clinics capture lesion images, inspect melanoma-risk signals, review model attention, and prepare cleaner documentation. It keeps the clinician in control while making AI output easier to understand and act on.
AI evidence
Risk, confidence, calibration, and attention are visible.
Clinician-led
Designed for review support, not autonomous diagnosis.
SaaS workflow
Capture, inspect, document, and hand off from one app.
Image input
Risk signal
Explainability
Boundary metrics
Risk support
73%
calibrated signal
Melanoma-risk signal 73%
Raw and calibrated probability are separated for review.
AI outputs
SaaS Product Preview
Open Dermascribe AppA focused AI workspace for skin lesion review.
Dermascribe is built around the core review moment: capture the lesion image, inspect the model evidence, and package the result for clinician-led follow-up.
Guided capture
Phone-first intake keeps the review workflow lightweight for smaller clinical teams.
Report-ready output
Clinicians can move from model evidence to cleaner documentation and handoff.
AI Output Stack
Skin lesion AI should show more than a score.
The Dermascribe app is strongest when it explains the image model output: calibrated melanoma-risk probability, decision thresholds, lesion heatmaps, boundary controls, and morphology proxies.
Melanoma-risk probability
73%
Decision support output
Raw and calibrated risk probability
Dermascribe separates the model signal from calibrated probability so clinicians can see what changed after calibration.
What clinicians can inspect
raw probabilitycalibrated probabilitymodel confidence
AI role
support
Claim type
not diagnostic
Final call
clinician
The Skin AI Gap
Most skin AI tools stop at the risk label.
Dermascribe makes model output inspectable: probability, calibration, attention, boundary, and morphology proxies are presented clearly while final judgment stays with the clinician.
Inconsistent Lesion Photos
Clinics often rely on ad hoc phone photos, creating variable image quality before AI review even begins.
Unclear Risk Prioritization
Clinicians need a fast second signal for which lesions deserve closer review, biopsy consideration, or referral.
Opaque AI Scores
A risk label alone is not enough. Clinicians need probability, confidence, calibration, and threshold context.
Weak Explainability
Many tools give a result without showing attention coverage, boundary behavior, or morphology proxy signals.
Missing Boundary Detail
The estimated perimeter, asymmetry, circularity, and color variation are often hidden or not exposed at all.
Hardware Dependency
Premium dermoscopy and total-body imaging systems are powerful, but expensive and high-friction for smaller clinics.
Skin AI Outputs
The product differentiates on what the AI reveals.
The value is a lightweight skin lesion AI workflow that exposes risk probability, calibration, explainability, and proxy morphology without requiring a heavy imaging setup.
Risk Signal
Melanoma-Risk Probability
Shows calibrated risk probability, model confidence, and a clinician-friendly state: elevated concern or benign-leaning.
Calibration
Raw vs Calibrated
Technical view exposes raw probability, calibrated probability, calibration temperature, and operating mode.
Explain
Lesion Heatmaps
Heatmap coverage and concentration help clinicians understand which visual regions affected the model output.
Boundary
Boundary Thresholding
The estimated perimeter can be inspected and tuned through threshold controls without treating it as anatomical size.
Signals
Morphology Proxy Signals
Surfaces lesion area, asymmetry, circularity, boundary complexity, and color variation as transparent non-diagnostic proxies.
Safety
Clinician-in-the-Loop
Every output is decision support. The app avoids presenting AI as a diagnosis or treatment decision.
Skin AI Review Flow
From image to explainable AI evidence.
This flow is intentionally about skin lesion review support, not broad clinic operations. The core promise is to make the image model easier to inspect and challenge.
1
Capture the lesion image
Use a standard phone image to start the skin AI workflow without special imaging hardware.
2
Calculate melanoma-risk signal
Generate probability, confidence, and elevated-concern state for clinician review.
3
Expose thresholds and mode
Show raw vs calibrated probability, high-risk threshold, and operating mode.
4
Inspect lesion heatmaps
Reveal where the model focused and how broad or concentrated the heatmap signal is.
5
Review boundary proxies
Inspect boundary threshold, lesion area proxy, asymmetry, complexity, and color variation.
6
Clinician makes the call
Use the AI output as decision support, with final interpretation left to the clinician.
Decision support, always
Dermascribe is a clinician-review tool. It can prioritize and explain image signals, while clinical decisions remain with the treating clinician.
Why Dermascribe
Positioned between consumer apps and hardware-heavy systems.
Dermascribe focuses on the lightweight explainability layer: melanoma-risk probability, calibration, lesion heatmaps, boundary controls, and morphology proxies without a heavy setup.
Lightweight
Targets image-based lesion review without forcing a premium dermoscopy or total-body imaging setup.
Transparent
Shows thresholds, calibration, and proxy metrics instead of hiding the model behind a single risk label.
Explainable
Combines lesion heatmaps, boundary visualization, and image comparison for clinician review.
Clinic-Ready
Designed for clinicians to review and override. It avoids autonomous diagnostic positioning.
Phone-based lesion capture
Consumer Apps
LimitedHardware Systems
LimitedTriage Devices
Dermascribe
No dedicated imaging tower for core workflow
Consumer Apps
Hardware Systems
LimitedTriage Devices
Dermascribe
Melanoma-risk probability output
Consumer Apps
Hardware Systems
Triage Devices
Dermascribe
Raw vs calibrated probability
Consumer Apps
LimitedHardware Systems
LimitedTriage Devices
Dermascribe
Visible high-risk threshold/mode
Consumer Apps
LimitedHardware Systems
LimitedTriage Devices
Dermascribe
AI lesion heatmap overlay
Consumer Apps
Hardware Systems
LimitedTriage Devices
Dermascribe
Adjustable lesion boundary threshold
Consumer Apps
Hardware Systems
Triage Devices
Dermascribe
Morphology proxy metrics
Consumer Apps
Hardware Systems
LimitedTriage Devices
Dermascribe
Clinician-in-the-loop wording
LimitedConsumer Apps
Hardware Systems
Triage Devices
Dermascribe
Comparison is directional and based on publicly available product positioning. Dermascribe is clinical decision support; final decisions remain with qualified clinicians.
Clinical Value
Better evidence, clearer review decisions.
Dermascribe is built around review quality and workflow clarity. Economic impact should be validated in pilots before being treated as a claim.
Support biopsy triage
Clearer AI evidence may help clinicians distinguish cases that need closer review from lower-concern images.
Prioritize concerning lesions
Elevated risk signals can help teams review suspicious lesions sooner while keeping final decisions clinical.
Reduce avoidable friction
A lightweight image workflow may reduce manual photo handling, repeat review steps, and unnecessary follow-up effort.
Dermascribe is clinical decision support. It does not replace clinician judgment, confirm cancer, or determine treatment. Pilot results should drive any final clinical or savings claims.
About
Oleskiew Sharma Research
Dermascribe is developed by Oleskiew Sharma Research (OSR), focused on practical AI systems that reduce clinical workflow friction. OSR builds tools grounded in real clinical environments — prioritizing explainability, clinician trust, and meaningful workflow integration over novelty.
Practical AI SystemsClinical Workflow FocusExplainability-FirstClinician Trust
Demo Requests Open
See how Dermascribe fits your workflow.
Request a demo for the skin lesion review workflow, or open the live Dermascribe app if you already have access.
Email: admin@dermascribe.ca